Business Context and Reporting Period
This Form 8-K Current Report was filed by Aclaris Therapeutics, Inc. on August 27, 2021. The report discloses material legal developments regarding two separate litigation matters: a consolidated stockholder derivative action and a consolidated securities class action.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal proceedings and corporate governance matters rather than financial performance metrics.
Material Changes and Legal Developments
- Derivative Action Settlement: On August 18, 2021, the U.S. District Court for the Southern District of New York granted preliminary approval for the settlement of the consolidated derivative action (In re Aclaris Therapeutics, Inc. Derivative Litigation). The settlement requires the Company to implement corporate governance reforms. Attorneys' fees for plaintiffs' counsel will be paid by the Company's insurer. The settlement is subject to final court approval.
- Securities Class Action Settlement: On the same date, the Court granted preliminary approval for the settlement of the consolidated securities class action (Rosi v. Aclaris Therapeutics, Inc., et al.). Details regarding this settlement are being communicated directly to potential class members via a claims administrator website.
Outlook, Risks, and Contingencies
Both proposed settlements are contingent upon final approval by the Court. If approved, the derivative action will be dismissed with prejudice, and the Company will be released from the claims by the plaintiffs. The filing notes that information contained in the exhibits and external websites does not constitute part of the filed report for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the status of the final court approval for both the derivative action and the securities class action settlements.
- Review the specific corporate governance reforms the Company is required to implement under the derivative action settlement.
- Confirm the total amount of attorneys' fees to be paid by the Company's insurer, if disclosed in the attached exhibits.
- Monitor the claims administrator website (www.strategicclaims.net) for updates regarding the securities class action settlement terms.